| Literature DB >> 28471409 |
Minlong Wang1, Peng Rui2, Caixiu Liu3, Ying Du4, Peiwen Qin5, Zhiqiu Qi6, Mingshan Ji7, Xinghai Li8, Zining Cui9,10.
Abstract
Sulfonyl-containing compounds, which exhibit a broad spectrum of biological activities, comprise a substantial proportion of and play a vital role, not only in medicines but also in agrochemicals. As a result increasing attention has been paid to the research and development of sulfonyl derivatives. A series of thirty-eight 2-substituted phenyl-2-oxo- III, 2-hydroxy- IV and 2-acyloxyethylsulfonamides V were obtained and their structures confirmed by IR, ¹H-NMR, and elemental analysis. The in vitro and in vivo bioactivities against two Botrytis cinerea strains, DL-11 and HLD-15, which differ in their sensitivity to procymidone, were evaluated. The in vitro activity results showed that the EC50 values of compounds V-1 and V-9 were 0.10, 0.01 mg L-1 against the sensitive strain DL-11 and 3.32, 7.72 mg L-1 against the resistant strain HLD-15, respectively. For in vivo activity against B. cinerea, compound V-13 and V-14 showed better control effect than the commercial fungicides procymidone and pyrimethanil. The further in vitro bioassay showed that compounds III, IV and V had broad fungicidal spectra against different phytopathogenic fungi. Most of the title compounds showed high fungicidal activities, which could be used as lead compounds for further developing novel fungicidal compounds against Botrytis cinerea.Entities:
Keywords: Botrytis cinerea; acetophenone; ethylsulfonamides; fungicidal activity; structure-activity relationship; synthesis
Mesh:
Substances:
Year: 2017 PMID: 28471409 PMCID: PMC6154733 DOI: 10.3390/molecules22050738
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Design strategy of the title compounds.
Scheme 1Synthesis of compounds III, IV and V.
The EC50 values of all the title compounds against 2 kinds of B. cinerea in vitro.
| Compd. | DL-11 | HLD-15 | ||
|---|---|---|---|---|
| EC50 (mg L−1) | 95% Confidence Limit (mg L−1) | EC50 (mg L−1) | 95% Confidence Limit (mg L−1) | |
| 8.67 | 6.41–11.73 | 16.25 | 11.82–22.33 | |
| 10.81 | 6.81–17.16 | 17.70 | 10.99–28.51 | |
| 7.51 | 5.14–10.99 | 8.12 | 6.22–10.61 | |
| 8.54 | 6.38–11.44 | 8.61 | 6.01–12.33 | |
| 5.44 | 3.18–9.30 | 7.94 | 5.83–10.82 | |
| 8.60 | 6.71–11.00 | 7.91 | 5.89–10.62 | |
| 3.98 | 2.86–5.52 | 8.00 | 6.05–10.58 | |
| 2.68 | 1.96–3.67 | 4.16 | 2.82–6.15 | |
| 5.15 | 3.79–7.01 | 7.22 | 5.01–10.40 | |
| 3.82 | 2.58–5.65 | 5.40 | 3.66–7.97 | |
| 4.07 | 2.95–5.59 | 6.83 | 4.83–9.67 | |
| 4.69 | 3.05–7.23 | 6.89 | 5.10–9.31 | |
| 1.58 | 1.03–2.43 | 3.48 | 2.37–5.12 | |
| 2.02 | 1.68–2.36 | 3.97 | 2.76–5.71 | |
| 1.64 | 1.15–2.34 | 8.53 | 5.16–14.12 | |
| 5.67 | 4.19–7.67 | 6.48 | 4.69–8.95 | |
| 7.15 | 5.29–9.67 | 7.74 | 5.45–10.99 | |
| 14.25 | 10.08–19.02 | 22.79 | 19.22–27.74 | |
| 13.33 | 10.29–17.27 | 33.16 | 23.80–46.20 | |
| 3.01 | 2.25–4.03 | 7.17 | 5.50–9.34 | |
| 3.50 | 2.59–4.72 | 4.07 | 2.92–5.68 | |
| 0.74 | 0.38–1.44 | 2.49 | 1.72–3.59 | |
| 0.70 | 0.38–1.30 | 0.61 | 0.28–1.35 | |
| 0.10 | 0.02–0.45 | 3.32 | 2.26–4.88 | |
| 1.96 | 1.18–3.25 | 4.69 | 3.05–7.23 | |
| 6.10 | 4.01–9.27 | 132.52 | 54.23–323.82 | |
| 14.27 | 9.43–21.58 | 3648.50 | 197.38–67442.80 | |
| 1383.25 | 116.31–16450.90 | 1443.05 | 184.66–11277.00 | |
| 131.12 | 39.92–430.68 | / | / | |
| 11.72 | 7.33–18.73 | 9.80 | 5.63–17.07 | |
| 1.32 | 0.80–2.17 | 13.80 | 9.20–20.71 | |
| 0.01 | 0.00–0.22 | 7.72 | 5.81–10.25 | |
| 1.18 | 0.69–2.00 | 4.73 | 3.36–6.67 | |
| 5.82 | 3.84–8.82 | 119.32 | 44.64–318.93 | |
| 6.99 | 5.14–9.51 | 21.09 | 14.97–29.72 | |
| 35.18 | 14.78–83.75 | 825.50 | 111.18–6129.14 | |
| 23.63 | 17.45–32.00 | 338.33 | 130.28–780.13 | |
| 20.33 | 10.69–38.66 | 553.23 | 144.46–2118.63 | |
| 1279.16 | 117.52–13923.30 | 139.55 | 71.51–272.32 | |
| procymidone | 2.59 | 1.78–3.76 | 15.95 | 11.78–21.60 |
| chlorothalonil | 1.66 | 0.97–2.84 | 17.52 | 8.04–38.19 |
Control efficiency of all the title compounds against B. cinerea in vivo (500 mg L−1).
| Compd. | Control Efficiency (%) against Strain DL-11 ± SEM | Compd. | Control Efficiency (%) against Strain DL-11 ± SEM |
|---|---|---|---|
| 54.9 ± 9.1 | 58.2 ± 7.3 | ||
| 50.5 ± 9.5 | 67.1 ± 8.2 | ||
| 65.9 ± 8.1 | 62.9 ± 7.6 | ||
| 60.4 ± 8.6 | 70.8 ± 15.4 | ||
| 52.7 ± 9.3 | 69.2 ± 13.9 | ||
| 40.7 ± 10.4 | 67.1 ± 4.2 | ||
| 25.3 ± 11.8 | 68.3 ± 9.7 | ||
| 57.1 ± 8.9 | 61.45 ± 6.0 | ||
| 44.0 ± 10.1 | 71.3 ± 5.2 | ||
| 47.3 ± 9.8 | 68.3 ± 9.7 | ||
| 58.2 ± 8.8 | 70.8 ± 10.4 | ||
| 58.2 ± 8.8 | 65.4 ± 9.0 | ||
| 62.6 ± 8.4 | 71.3 ± 14.6 | ||
| 33.0 ± 11.1 | 66.7 ± 4.8 | ||
| 53.8 ± 9.3 | 68.3 ± 5.5 | ||
| 57.1 ± 8.9 | 74.6 ± 11.5 | ||
| 42.9 ± 10.2 | 73.3 ± 11.8 | ||
| 67.1 ± 8.7 | 67.1 ± 9.4 | ||
| 52.9 ± 7.4 | 67.9 ± 8.0 | ||
| procymidone | 72.5 ± 6.1 | pyrimethanil | 61.7 ± 8.1 |
The EC50 values of selected compounds III, IV and V against different phytopathogenic fungi in vitro.
| Compd. | EC50 (mg L−1) | |||
|---|---|---|---|---|
| Fg a | Tc a | Pa a | Pc a | |
| 8.27 | 1.39 | 10.49 | 3.7 | |
| 5.12 | 4.02 | 9.36 | 4.17 | |
| 4.72 | 1.65 | 14.53 | 3.06 | |
| 3.55 | 3.07 | 13.41 | 2.77 | |
| 1.41 | 0.99 | 7.25 | 2.25 | |
| 1.05 | 0.60 | 8.65 | 4.47 | |
| 2.84 | 2.46 | 11.42 | 6.02 | |
| 0.79 | 1.86 | 8.62 | 2.74 | |
| 3.26 | 3.67 | 11.17 | 4.26 | |
| 3.17 | 1.88 | 6.52 | 4.44 | |
| 7.48 | 15.2 | 27.33 | 28.4 | |
| 4.59 | 1.52 | 10.72 | 4.79 | |
| 9.8 | 1.57 | 19.94 | 5.6 | |
| 2.41 | 1.07 | 6.96 | 3.22 | |
| 4.13 | 2.33 | 16.92 | 3.18 | |
| chlorothalonil | 0.35 | 0.02 | 5.93 | 17.22 |
a Fg = Fusarium graminearum Schw.; Tc = Thanatephorus cucumeris; Pa = Pythium aphanidermatum; Pc = Phytophthora capsici Leonian.
Figure 2Structure elucidation of compounds III, IV and V: (a) 1H-NMR spectrum of compound III-13; (b) 1H-NMR spectrum of the compound IV-5; (c) 1H-NMR spectrum of compound V-12; (d) The proposed stable conformation of compound V-12.